As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations through Q3 2027, based on the current planned expenditures. During the third quarter of 2024, the Company raised $35.6 million of net proceeds pursuant to the Company’s ATM program by issuing 663,730 shares. In addition, on August 1, 2024, the Company’s made a final $11.8 million loan payment and the loan has been fully paid off.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Reveals Promising Obesity Treatment Data
- Corbus Pharmaceuticals presents new CRB-913 pre-clinical data at Obesity Week
- CRBP Upcoming Earnings Report: What to Expect?
- Corbus Pharmaceuticals completes enrollment for Phase 1 trial of CRB-701
- Largest borrow rate increases among liquid names